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          ABSTRACT 
SYNTHESIS AND FUNCTIONAL EVALUATION OF PEPTIDE-MODIFIED  
POLY(LACTIC-CO-GLYCOLIC ACID) NANOPARTICLES TO INHIBIT 
PORPHYROMONAS GINGIVALIS BIOFILM  
 
Paridhi Kalia  
 
 Dec 01, 2015 
 
Periodontal disease is an oral inflammatory disorder that afflicts roughly 46% of the 
adults in the U.S. Currently, treatment of periodontal disease involves the removal of 
plaque from the gingival pocket (with possible antibiotic treatment) and if necessary, 
gingival surgery. To our knowledge, no therapeutic approach exists that promotes host-
biofilm homeostasis by limiting pathogen recolonization of the oral cavity after 
prophylaxis or treatment. The interaction of the pathogen Porphyromonas gingivalis with 
commensal streptococci is critical for initiation of periodontitis and represents a target for 
limiting P. gingivalis colonization of the oral cavity. Previous studies showed that a 
synthetic peptide (BAR) derived from antigen I/II protein of Streptococcus gordonii 
potently inhibited P. gingivalis adherence to streptococci. However, BAR was less 
effective in preventing P. gingivalis adherence in a more complex three species biofilm 
model, suggesting that the potency of BAR against complex biofilms may be reduced. 
This study focuses on designing surface-modified poly(lactic-co-glycolic acid; PLGA) 
nanoparticles (NPs) that are functionalized with BAR to increase its inhibitory potency 
by multivalent binding with P. gingivalis. Biotinylated BAR was conjugated to the 
surface of avidin-palmitylated PLGA NPs. We generated NPs with particle size of 100 
vi	  	  
±28nm and Zeta Potential of -12mV. The surface modification of avidin-NPs with BAR 
was examined using two approaches.  Comparing the binding of biotin-PEG FITC with 
avidin-NPs and avidin-NPs that were reacted with biotinylated BAR showed that BAR 
binding efficiency was approximately 98%. In addition, reacting avidin-NPs with 
fluorescently labeled BAR showed that a concentration of 37.1 nmol BAR/mg NPs 
resulted in maximal BAR binding. We also showed that BAR-NPs bound to P. gingivalis 
in a dose-dependent manner and significantly (P<0.01) inhibited P. gingivalis/S. gordonii 
biofilm formation (50% inhibitory concentration = 0.29µM) making it 4.5 times more 
potent than soluble BAR. Together this platform represents a potential therapeutic 
approach to effectively target an initial interaction involved in P. gingivalis colonization  
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                                                             CHAPTER 1 
        INTRODUCTION 
 
According to the World Oral Report 2003, periodontal disease is among the most 
common microbial disease affecting the adult population worldwide and is one of the 
major oral health care problems globally. Periodontal disease is prevalent and occurs in 
46 % of adults in the U.S16,24,15 Severe disease (subgingival pocket depths > 6mm) occurs 
in 9% of U.S. adults1 and 11.2% of adults worldwide16,24. Domestically, this correlates to 
annual expenditures for the treatment and prevention of periodontal disease in excess of 
14 billion dollars16,15. 
Periodontal disease is an oral inflammatory disorder that is initiated by microbial 
biofilms that form in the subgingival pocket leading to severe chronic inflammation 
characterized by alveolar bone resorption and subsequent tooth loss21. The milder form of 
disease starts with gingival inflammation, termed as gingivitis. Gingivitis, if left untreated 
can lead to a more severe form of periodontal disease characterized by clinical 
attachment loss, termed as periodontitis21.  
 
Role of Periodontal Pathogens  
 
The resident organisms of dental plaque play a significant role in the onset and 
advancement of periodontal disease.8,22 Over 700 different species of bacteria colonize 
and interact with each other to form dental plaque14. In a state of health, the oral cavity 
is comprised of benign commensals, majorly Actinomyces and streptococci22. However 
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shifts in population, mainly gram-negative anaerobes may orchestrate periodontal 
disease. Even if these organisms are present in low abundance, they have they have the 
ability to remodel their local environment from a naturally benign microbiota to a 
dysbiotic environment,9,10,22. Among such organisms, Porphyromonas gingivalis have 
gained much attention,9,10,18. 
P. gingivalis colonizes in the subgingival plaque, but before transitioning in its 
primary niche, it first establishes itself in a relatively aerobic environment, where it 
interacts with commensal streptococci gordonii ,12,28. The interaction is mediated by two 
receptor-ligand pairs namely the the long and short fimbriae of P. gingivalis4,12,28. The 
long fimbrial subunit protein (FimA) interacts with cell surface glyceraldehyde-3-
phosphate dehydrogenase of S. gordonii8,9,10,12 whereas the minor fimbrial protein in P. 
gingivalis, interacts with streptococcal SspB5,10. SspB belongs to the cell surface protein 
in the antigen I/II protein that are present on the cell surface of nearly all the species of 
streptococci.8,9,10,12 . Prior studies suggested that purified P. gingivalis showed binding 
specificity with streptococci gordonii primarily because the Mfa1 of P. gingivalis did not 
interact with antigen I/II of S. mutans10. Furthermore, studies by Demuth et al.12 and 
Cook et al.6 showed that the interaction of P. gingivalis and S. gordonii mediated by 
Mfa1-SspB represented an essential initial event that facilitates P. gingivalis colonization 
in the oral cavity,9,10,18,28,36. 
 
Dental Plaque Formation and Disease Pathogenesis  
Dental plaque is a specific and highly variable structural entity consisting of 
microorganisms and their products embedded in a highly organized intercellular 
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matrix34,38.  It represents a community of microorganisms involved in a wide range of 
physical, metabolic and molecular interactions organized in an extracellular matrix32,33,34. 
This environment provides advantages to the organisms such as a broader habitat range 
for growth and enhanced resistance to antimicrobial agents and host defenses32,33,34. 
Understanding the formation and progression of dental plaque and hence, periodontal 
disease etiology will aid in developing novel therapies to prevent and treat periodontal 
diseases32.  
The process of dental plaque formation is complex, and involves several distinct 
phases, beginning with bacterial attachment to the tooth surface via the salivary pellicle 
that forms immediately following tooth eruption or tooth cleaning13. Following initial  
 
 attachment, adherent bacteria begin to proliferate and form microcolonies14,31. Each 
microcolony acts as an independent community and may contain a variety of bacterial 
species31. Bacteria that are located in the center of the microcolony usually live in a strict 
anaerobic environment, while others at the periphery of the microcolony are exposed to a 
more aerobic environment22. Therefore, a biofilm is a dynamic structure that can provide 
a range of environments with respect to nutrient and oxygen concentrations and thus may 
successfully harbor a diverse bacterial population31 To sustain these bacterial 
populations, a series of fluid channels exist between microcolonies to provide nutrients 
and oxygen required for normal bacterial growth and to facilitate outward movement of 
bacterial metabolites, waste products, and enzymes14,32,38. Additionally, each bacterial 
microcolony uses chemical signals to create a primitive communication system within the 
biofilm, a perfect niche for bacterial propagation and existence33,33,34. 
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Development of Dental Plaque  
The growth and development of dental plaque occurs in a four-phase process:  








Figure	  1:	  Schematic	  of	  biofilm	  formation.	  	  
 
Initial Attachment  
 The initial attachment of bacteria commences after the formation of the salivary 
pellicle. The pellicle is a thin coating of salivary proteins that adhere to the tooth surface 
within minutes after tooth eruption or cleaning. The pellicle is composed of albumin, 
glycoproteins, acidic proline-rich proteins, mucins, cell debris, amylase, lysozyme and 
sialic acid32,38. The pellicle provides a sticky base to support further colonization and 
propagation of bacteria. Acidic phosphoproteins and proline-rich proteins that aid in 
colonization of bacteria on to the tooth surfaces33 mediate the initial interaction 
between the pellicle and the bacteria.  In addition to the presence of pellicle, other 
environmental cues that can influence biofilm formation include low pH, changes in 
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osmolarity, and oxygen. The early plaque forming bacteria or the initial colonizers are 
generally Gram-positive cocci, which primarily comprise streptococcal species32,33,34.  
 
Rapid Growth Phase 
 Once microorganisms have established a foothold on the tooth surface, they 
undergo a series of changes. Common adaptations that have been observed include the 
expression of large quantities of exopolysaccharides that may protect the biofilm and 
lead to biocide resistance32,33,34 The biofilm grows through the attachment of new 
bacteria through a process of coaggregation17,25,26. Coaggregation is driven by specific 
receptor-ligand interactions that allow new bacterial colonizers to adhere to the 
previously attached cells and results in increased complexity of the microbial 
community17,25,26. A detailed knowledge of these mechanisms of bacterial attachment 
and co-adhesion could highlight mechanisms that may be exploited to control the 
pattern of biofilm formation32,33,34,38. For example, analogs could be synthesized that 
block adhesin-receptor attachment or co-adhesion or alternatively, chemical 
modification of the colonizing surface could make them less conducive to microbial 
colonization.  
 
Steady State Phase and Detachment 
 As plaque matures in the subgingival pocket, the host mounts an inflammatory 
response to the microbial challenge and the flow of gingival crevicular fluid (GCF) is 
increased32,38. The GCF not only delivers components of host defense but also serves as a 
continuous source of glycoproteins and co-factors that provide nutrients for the growing 
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microorganisms38. In addition, bacterial microcolonies produce degradative enzymes 
such as endotoxins and lipoteichoic acid that promote an inflammatory response in the 
gingival tissue34,38. Furthermore, the inflammatory host response and increased secretion 
of GCF leads to a transient increase in the local pH. This increase in pH favors the 
growth of anaerobic bacteria such as Prevotella intermedia and P. gingivalis34,38. As 
gingivitis progresses to periodontitis, the microflora can become even more diverse34,38. 
Periodontitis results in tissue damage, which is manifested clinically as attachment loss. 
Tissue damage results from the activity of the subgingival microflora and indirectly from 
the release of lysosomal enzymes during phagocytosis or by the production of cytokines 
that stimulate resident connective tissue cells to release metalloproteinases.  
 Detachment to the planktonic phase can occur by a variety of active or passive 
processes. For example, some organisms may express enzymes that degrade the 
extracellular matrix leading to cell dispersion, while other organisms may reduce the 
expression of enzymes that are required for biosynthesis of the matrix.  Portions of the 
mature biofilm may also simply slough off and colonize elsewhere. 
Implication for the Etiology of Periodontal Diseases 
There are two main hypotheses that explain the role of plaque bacteria in 
disease19,20. First, the “Specific Plaque Hypothesis” proposes that out of the diverse 
species that exist in dental plaque, only specific species are actively involved in causing 
disease even if these species are present in low abundance11,19,20,31,30,39. Consistent with 
this, specific organisms such as P. gingivalis, T. forsythia, and T. denticola have all been 
strongly associated with adult periodontitis4,5,8,10,23,35. Furthermore, recent studies also 
suggest that P. gingivalis may play a pivotal role in disrupting host-microbe homeostasis 
	  7	  	  
and function as a “keystone” pathogen even when present at low abundance in a complex 
multispecies biofilm28,29,30. These studies further indicate that by altering the host 
response, P. gingivalis induces changes in microbial populations in the biofilm leading to 
uncontrolled inflammation and tissue damage. However, the Specific Plaque Hypothesis 
cannot adequately explain the absence of the putative pathogens in some cases of disease 
nor the presence of these pathogenic organisms in healthy patients19.  In contrast, the 
"Non-Specific Plaque Hypothesis" purports that many of the heterogeneous mixture of 
organisms in plaque could play a role in disease, and that disease is a result of the overall 
interaction of the plaque microflora with the host19. It is well established that plaque 
mediated diseases has multi factorial etiology and a variety of organisms are involved in 
its progression. Therefore, the specific plaque theory is puzzling, however it does 
demonstrates some specificity with respect to disease causing organisms. Consequently, a 
modified hypothesis was proposed which suggested that changes in environmental factors 
lead to a shift in the resident microflora resulting in microbial dysbiosis19. The occurrence 
of potentially pathogenic species as minor members of the resident plaque microflora 
would be consistent with this proposal19. In health, these organisms would be weakly 
competitive and mostly be suppressed by intermicrobial antagonism, so that they would 
comprise only a small percentage of the plaque microflora and would not be significant 
clinically19. Microbial specificity in disease would be due to the fact that the new 
environmental conditions would activate only a certain group of microorganisms. It is a 
basic tenet of microbial ecology that a major change to an ecosystem produces a 
corresponding disturbance to the stability of the resident microbial community19.  
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Significance of Porphyromonas gingivalis and Streptococcus gordonii Interaction in 
Dental Plaque Biofilm Formation  
Previous work suggests that the adherence of P. gingivalis to oral streptococci is 
an initial event that facilitates P. gingivalis colonization of the oral cavity8,9 . Adherence 
is driven by a protein-protein interaction between the minor fimbrial antigen (Mfa1) of P. 
gingivalis and antigen I/II (AgI/II) of specific streptococcal species5,8,9,10,12. This 
interaction is mediated by a specific motif in AgI/II, designated BAR8,9. A synthetic 
peptide representing BAR potently inhibited the formation of P. gingivalis/S. gordonii 
biofilms in vitro (IC50=1.3µM)8,9,10 and significantly reduced  P. gingivalis virulence in 
mice that harbor S. gordonii when administered simultaneously with P. gingivalis 
infection9. These results suggest that BAR peptide blocks P. gingivalis colonization of 
the oral biofilm and may represent an effective therapy to limit recolonization of the oral 
cavity by P. gingivalis after professional prophylaxis. However, a limitation of this 
potential therapeutic approach is that BAR can only be transiently administered. In 
addition, while BAR potently inhibits the formation of two species biofilms, it is less 
effective in disrupting preformed biofilms or more complex communities, which required 
a higher concentration (i.e., IC50 =3.6µM)18 and/or prolonged exposure to BAR (i.e., > 60 
minutes)10,7. Together, these data suggest that BAR is more effective inhibiting the initial 
association of P. gingivalis and streptococci than disrupting established complex 
biofilms8,10,18. This represents a potential limitation for developing the peptide as a 
therapeutic for clinical evaluation in humans. Therefore, the goal of this study was to 
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develop a method to deliver higher localized concentrations of BAR to the oral cavity to 
improve BAR effectiveness. Our hypothesis is that nanotechnology may be applied to 
develop novel non-toxic, poly(lactic-co-glycolic acid; PLGA) nanoparticle (NP) delivery 
vehicles that increase BAR effectiveness by promoting multivalent surface interactions of 
BAR with P. gingivalis.  
 
Nano-sized Technology in Advanced Therapeutics 
In recent times, many therapeutic agents have been developed to treat or prevent 
dental caries and periodontal disease – the two major oral biofilm-associated infections2. 
Traditionally these therapeutic agents have been comprised of antimicrobials that are 
delivered to target tissues via oral, subcutaneous or local delivery routes40,27.  When 
administered via oral doses, these agents are often destroyed either by enzymes in saliva 
or during intestinal transit resulting in decreased efficacy50,51. Moreover, uncontrolled 
levels of antimicrobials may lead to concentration spikes resulting in serious side effects 
and toxic reactions40,27. On the other hand, localized drug delivery vehicles including 
strips, gels and antimicrobial membranes have difficulty accessing the periodontal 
pockets and resisting recolonization by pathogens, rendering them only partially 
successful2. In contrast to these technologies, delivering antimicrobial molecules via NPs 
may circumvent many of the challenges mentioned above, thereby producing more 
effective therapeutics27.  
NP drug delivery systems offer many advantages over conventional prophylaxes 
or therapeutics. One advantage of NPs is that their small size enables them to more 
effectively penetrate barriers and allow for drug accumulation at target sites, resulting in 
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enhanced treatment efficiency40. NPs have been developed using a variety of materials 
including metals, ceramics and polymers40,2,1. Among several biomaterials, particles 
made of colloidal gold, iron oxide crystals, hydroxyapatite and silver have been used as 
antimicrobial agents to prevent dental caries2,1. The proposed mechanism of these 
antibacterial metallic particles is believed to arise from an electrostatic attraction of 
positively-charged NPs with the negative charge of the bacterial cell membrane1. 
Furthermore, NPs have been investigated for a range of applications including 
incorporation into dentures, orthodontic adhesive materials and dental resin composites 
for preventing secondary caries2. Other novel systems based on silica have been 
investigated for anti-biofilm properties2. In particular, the use of nitric-oxide-releasing 
silica NPs to kill biofilm-based microbial cells has recently been investigated2. The rapid 
diffusion of NO may result in enhanced penetration of oral biofilm and thereby, improved 
anti-biofilm properties2. Although the development and the application of 
nanotechnology have shown immense promise, there have been considerable concerns 
regarding the potential toxicity associated with metallic NP accumulation in different 
tissues and organs1. To circumvent the challenge of metal cytotoxicity, polymeric NPs 
have been developed to provide safer and more durable options for drug delivery55. In 
addition, they offer biocompatibility and flexible tuning of physical properties to achieve 
desired dosages and drug release profiles27. 
Polymeric Nanoparticles 
Synthetic and natural polymeric NPs have been extensively researched as 
potential vehicles for drug delivery49. Synthetic polymers have the advantage of high 
purity over natural polymers and may be less likely to evoke an immune response (i.e., 
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less immunogenic) 40,27. Among the variety of synthetic options, poly(lactic acid) (PLA), 
poly(ε-caprolactone) (PCL), polyethyleneimine, and poly(glycolic acid) (PGA) are 
extensively used in preventing oral biofilms because of their biodegradability and 
biocompatibility27. Among the different polymeric materials, poly(lactic-co-glycolic 
acid) (PLGA) has attracted considerable attention due to its FDA approval for human 
therapy27. Furthermore, PLGA NPs have well described formulations that can deliver a 
variety of agents, e.g. hydrophilic or hydrophobic small molecules or macromolecules27. 
Currently, PLGA NPs have been investigated for their use in bone loss in severe 
periodontitis2. Another interesting use of PLGA NPs is in photodynamic therapy, which 
is a novel alternative to conventional antimicrobials2. Photodynamic therapy works on the 
concept that a photosensitive agent, which absorbs light, can be preferentially 
incorporated into bacteria and subsequently activated by light. Activation leads to the 
generation of singlet oxygen and free radicals that are cytotoxic to bacterial cells2.  For 
this, PLGA NPs are coupled with photosensitive methylene blue (MB)2. PLGA/MB NPs 
have proven to be effective against various Gram positive and Gram-negative bacteria 
associated with endodontic and periodontal infections2. Furthermore, 
dexamethasone/PLGA NPs have been extensively studied for their osteoblastic 
differentiation in periodontal disease2. In summary, PLGA NPs provide a biocompatible, 
non-immunogenic, biologically stable carrier that can encapsulate and/or present on its 
surface a wide range of biologically active molecules of therapeutic significance2,27. Even 
though additional studies are required to understand the behavior of particles in 
preventing oral infections, it is important to note that these polymeric NPs are a 
promising alternative to conventional antimicrobials27. 
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                                                        CHAPTER 2 
     HYPOTHESIS AND SPECIFIC AIMS 
 
Therapeutic approaches that target specific periodontal pathogens or groups of 
organisms are lacking. Currently, treatment of periodontal disease involves the removal 
of plaque from the gingival pocket (with possible antibiotic treatment) and if necessary, 
gingival surgery to reduce pocket depth. To our knowledge, no therapeutic approach 
exists that promotes host-biofilm homeostasis by limiting pathogen colonization of the 
biofilm or recolonization after prophylaxis or treatment. To develop an approach that 
specifically targets pathogen interactions, this project builds upon our previous discovery 
of a peptide that specifically inhibits P. gingivalis colonization of the oral biofilm. We 
seek to develop peptide delivery PLGA-NPs that not only target P. gingivalis, but also 
deliver BAR to niches in the oral cavity where it will be most effective. We anticipate 
that these targeted NPs will deliver BAR at higher localized concentrations to specific 
niches in the oral cavity or microbiome. While tissue targeted NPs have been used 
against a variety of pathologies, their application and targeting to specific organisms and 
niches in the oral microbiome represents a novel approach to combat periodontal disease. 
 
Specific Research Hypothesis  
Surface-modified NPs will facilitate multivalent interactions between BAR and  
the minor fimbrial antigen leading to increased inhibition of P. gingivalis adherence to 
streptococci relative to equimolar amounts of free BAR peptide. 
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Specific Aims 
To compare the inhibitory potency of BAR-NPs with soluble BAR we will: 
1. Synthesize PLGA NPs that are surface-modified with BAR peptide to facilitate 
multivalent interaction with P. gingivalis.  
2. Quantify the density of BAR peptide on the NP surface to optimize the concentration 
of BAR surface modification.  
3. Compare the efficacy of BAR-NPs with the molar equivalent of free BAR peptide 
using dual and three biofilm model systems.  
 

























   MATERIALS AND METHODS  
 
Peptide Synthesis 	  
The BAR peptide used in this study, is shown in Table 1. The peptide is 
comprised of residues 1167 to 1193 of the SspB (Antigen I/II) protein sequence of S. 
gordonii16. The peptide containing a covalently attached biotin at its N-terminus was 
synthesized by BioSynthesis, Inc. (Lewisville, TX) and was obtained at more than 85% 
purity. 
 
Table 1: Sequence of BAR peptide.  
Peptide Peptide Sequence 
BAR NH2-LEAAPKKVQDLLKKANITVKGAFQLFS-OH 
 
  To assess the level of BAR present on the NP surface, biotin-BAR was also 
synthesized that contained 6-carboxyfluorescein (Flc) covalently attached to the epsilon 
amine of the lysine residue underlined in Table 1 to generate BAR-Flc.  For functional 
controls with free peptide, BAR without biotin or fluorophore was utilized.
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Growth of Bacterial Strains 
P. gingivalis strain ATCC 33277 was grown in Trypticase soy broth media (TSBY 
media) (Difco) supplemented with 0.5% (w/v) yeast extract, 1 µg/ml (final concentration) 
menadione, and 5 µg/ml (final concentration) hemin. Twenty milliliters of medium was 
reduced for 24 hr under anaerobic conditions consisting of 10% CO2, 10% H2, and 80% 
N2. Next, P. gingivalis was inoculated into the medium and grown for 48 hr at 37°C 
under anaerobic conditions.  S. gordonii DL-1 was cultured aerobically without shaking 
in brain-heart infusion (BHI) broth supplemented with 1% yeast extract for 16 hr at 37°C. 
Synthesis of Avidin-Palmitate Conjugates 	  
  To obtain BAR-modified PLGA NPs, the NP surfaces were modified with avidin-
palmitate to attach biotinylated BAR. Avidin-palmitate was conjugated as previously 
described by Fahmy and Saltzman. Briefly, 100 mg/8 ml solution of avidin was made in 
2% (w/v) sodium deoxycholate (NaDC) in PBS and warmed to 37ºC. 4.5 mg/2 ml 
solution of palmitic acid-NHS (PA-NHS, Sigma) was prepared in 2% (w/v) NaDC and 
sonicated until well-mixed. Two milliliters of the above made PA-NHS solution was 
added dropwise to the reaction vial containing avidin, and reacted overnight at 37ºC. The 
following day, the reaction was dialyzed in 1200 mL of 0.15% (w/v) NaDC in PBS 
heated to 37ºC using a 3500 molecular weight cut off (MWCO) dialysis tubing to remove 
free PA-NHS. After overnight dialysis at 37ºC, complexed avidin-palmitate was 
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Nanoparticle Synthesis 
	  
  Unmodified and surface-modified PLGA NPs, encapsulating the fluorescent dye 
Coumarin 6 (C6) for binding and internalization studies were synthesized and 





Figure 2: Overview of NP synthesis with an example of the resulting NP morphology 




BAR-Modification of C6 NPs  
    C6 NPs were synthesized using an oil-in-water (o/w) single emulsion technique31. 
Briefly, C6 was encapsulated in 100-200 mg poly(lactic-co-glycolic acid) (PLGA) 
carboxyl-terminated polymer (0.55-0.75 dL/g, LACTEL®). C6 was dissolved in 
methylene chloride (DCM) overnight at a concentration of 15 µg C6 per mg of PLGA. In 
parallel, 200 mg PLGA crystals were dissolved in 2 ml of DCM overnight. The following 
day, the PLGA/DCM solution was vortexed while adding 200 µl of the prepared C6 
DCM solution. The PLGA/DCM/C6 solution was sonicated to attain a uniform solution. 
Next, 2 ml of 5% (w/v) polyvinyl alcohol (PVA) solution was mixed with 2 ml of 10 
mg/ml avidin-palmitate to obtain a well-mixed solution. To create the single emulsion, 2 
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mL PLGA/DCM/C6 solution was added dropwise to 4 ml PVA/avidin-palmitate under 
vortexing and subsequent sonication. The residual DCM was evaporated by adding the 
NP solution to 50 mL of 0.3% PVA for 3 hr while mixing. After solvent evaporation, the 
50 ml NP solution was transferred to tubes and centrifuged at 13,000 rpm at 4°C to wash 
NPs, prior to BAR-peptide conjugation. The supernatant was discarded and the pelleted 
NPs were resuspended in 9 ml of diH2O. The resuspended NPs were incubated for 30 min 
on a benchtop rotator with biotinylated BAR peptide at a molar ratio of 3:1 BAR:avidin 
(18.5 nmol/mg) in PBS. After conjugation, the NPs were centrifuged at 13,000 rpm and 
the supernatant was discarded. The NPs were resuspended in 20 ml diH2O and 
centrifuged twice to remove any remaining unbound BAR peptide. After the three 
washes, the NPs were suspended in 9 ml of diH2O, transferred to a 10 ml cryotube, 
frozen in -80°C for 3 hr and subsequently lyophilized. All NPs were stored at -20ºC after 
synthesis. Unmodified C6 NPs were prepared similarly, however 5% (v/v) PVA alone 
was added instead of PVA/avidin-palmitate solution. 
 
Nanoparticle Characterization 	  
Particle size and morphology were determined using scanning electron 
microscopy (SEM). Dry NPs were mounted on carbon tape and sputter coated with gold 
under vacuum. Average particle diameter and size distribution were determined from 
SEM images of at least 400 particles per batch using image analysis software (ImageJ, 
National Institutes of Health). Zeta potential and dynamic light scattering (DLS) were 
measured with a Zetasizer Nano ZS (Malvern) in diH2O to determine particle charge and  
hydrated diameter. NPs with zeta potential values ranging from +25 mV to -25 mV 
	  18	  	  
typically have high degrees of stability, indicating less potential for NP aggregation.  
Functional Characterization 	  
As described below, indirect and direct methods were used to quantify the density of 
BAR peptide on the NP surface.  
1. Indirect: The binding of biotin-PEG-FITC to both avidin-NPs and BAR-NPs was 
measured (Figure 3). 
2. Direct: The binding of fluorescently-labeled BAR peptide to avidin-NPs was 
measured (Figure 4).  













Figure 3: Schematic of the indirect method of NP characterization. Avidin-NPs 
and BAR-NPs were reacted with saturating concentrations of Biotin-PEG-FITC 
and NP associated fluorescence was determined. The fluorescence values were 
converted to an amount of PEG-FITC in both cases and the obtained values were 
then subtracted. The difference in the amount of PEG-FITC bound to of BAR-NPs 
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Avidin-NPs (20 mg) were synthesized and aliquoted to a 15 ml tube. These NP 
swere reacted with 18.5 nmol/mg of biotin-PEG-FITC for 1 hr on a rocker platform in 
the dark. PEG3400 was used to quantify binding indirectly since it is similar in 
molecular weight to biotinylated BAR (3400 vs. 3329 Daltons). The concentration of 
biotin-PEG-FITC used in these reactions (i.e., 18.5 nmol/mg) was determined by first 
calculating the total number of available biotin binding sites on surface-modified avidin, 
with the assumption that each avidin molecule has 2 available biotin binding sites, and 
then adding biotin-PEG-FITC at a molar ratio of 3:1 biotin-PEG-FITC: biotin binding 
sites. After conjugation, the NPs were washed twice with diH2O by centrifugation at 
15,000 rpm. After synthesis, the washed particles were frozen, lyophilized and stored at 
-20ºC. The following day, the biotin-PEG-FITC labeled NPs were suspended in freshly 
prepared 1X PBS (10 mM NaH2PO4, 137 mM NaCl, and 2.7 mM KCl, pH 7.4) at 1 
mg/mL and subsequently diluted 1:2, 1:5 and 1:10-fold in PBS.  Samples (100 µl each) 
were then transferred into a microtiter plate in triplicate. 
A standard curve of biotin-PEG-FITC was obtained by making serial dilutions of 
a 1 mg/ml biotin-PEG-FITC stock solution to generate a concentration range of 0.002 to 
5 µg/ml biotin-PEG-FITC. The diluted NP samples and standards were measured for 
fluorescence at 488nm. The amount of bound biotin-PEG was determined from the 
standard curve generated with biotin-PEG-FITC. This identified the density of biotin-
PEG-FITC on the NP surface resulting from a given set of reaction conditions and also 
identified the concentration of biotin-PEG-FITC required to saturate the avidin present on 
the NP surface. Next, another aliquot of avidin-modified NPs was conjugated with 
biotinylated BAR and the resulting BAR-NPs were subsequently incubated with a 
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saturating concentration of biotin-PEG-FITC (i.e., 18.5 nmol of biotin-PEG-FITC per 1 
mg NPs).  NP-associated fluorescence was determined as above and the amount of bound 
biotin-PEG-FITC was determined from the standard curve.  Total BAR modification was 
calculated with the following equation:  [biotin-PEG-FITC associated with avidin-NPs] - 
[biotin-PEG-FITC associated with BAR-modified NPs]. This difference represents the 
amount of BAR conjugated to the NP surface. 

















Figure 4: Schematic of the direct characterization method. Avidin-NPs were 
reacted with increasing concentrations of fluorescently BAR-Flc and compared 
 to a standard of known labeled BAR concentrations to quantify labeled BAR 
binding on the NP surface. 
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The second approach that was used to quantify BAR binding was to directly 
measure BAR binding to avidin-NPs. This was accomplished using biotinylated BAR in 
which an internal lysine was labeled with 6-carboxyfluorescein Flc, (see Table 1). 
Avidin-NPs (5 mg) were aliquoted to eppendorf tubes and mixed with increasing 
concentrations (3-, 6-, 9-, 18- fold molar access of BAR) (18.5 – 111.2 nmol/mg NP) of 
fluorescently labeled BAR (BAR-Flc) for 45 min on a rocker platform in the dark. After 
conjugation, the NPs were washed twice with diH2O after centrifugation at 15,000 rpm. 
The washed samples were frozen, lyophilized and stored at -20ºC after synthesis. On day 
2, NPs from each eppendorf tube were aliquoted and suspended in 1X PBS to attain 
suspensions of 1 mg NP/ml. The resulting samples were transferred to a microtiter plate 
in triplicate. After conjugation with BAR-Flc, total NP-associated fluorescence was 
calculated from a standard curve obtained from known BAR-Flc concentrations. Both 
the indirect and direct approaches described above allowed us to quantify the amount of 
BAR peptide bound to the NP surface and enabled us to optimize the synthesis and 
conjugation conditions to obtain maximal binding of BAR to the NP surface. Surface-
modification using avidin-biotin linkages represent an established and efficient method 
to conjugate our novel peptide to the NP surface56. 
P. gingivalis Binding Assay 	  
The adherence of BAR-NPs to P. gingivalis was assayed using BAR-modified 
NPs that encapsulated the fluorescent probe C6.  P. gingivalis was cultured as previously 
described and to establish a uniform cell concentration across all samples, P .gingivalis 
suspensions were adjusted to a final optical density of 0.4. Subsequently, a 1 ml aliquot 
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of P. gingivalis cells was transferred into eppendorf tubes and mixed with increasing 
concentrations of BAR-modified C6 encapsulated NPs (1 µg/ml, 2.5 µg/ml, 5 µg/ml, 
and 10 µg/ml) for 45 - 60 mins on a rocker platform in the dark. Negative controls for 
this experiment consisted of: 1) P. gingivalis incubated with unmodified C6 NPs and 2) 
BAR-modified C6 NPs incubated in buffer without P. gingivalis to evaluate nonspecific 
binding. After incubation, the samples were centrifuged at 5600 rpm for 5 min and the 
supernatant was discarded to remove the unbound particles. The remaining cells were 
resuspended in 1X PBS. One hundred microliters of each sample were transferred to a 
microtiter plate and the cell bound fluorescence was measured at 488 nm.   
Dual Species Biofilm 	  
Cultures of P. gingivalis and S. gordonii were obtained as previously described. 
S. gordonii DL-1 cells were harvested by centrifuging a 12 ml culture of S. gordonii at 
5600 rpm for 5 min. The supernatant was discarded and the cell pellet was resuspended 
in 1 ml of 1X PBS.  S. gordonii was labeled with 20 µl of 10 mM  hexidium iodide (5 
mM, Molecular Probes, Eugene, OR) for  15 min at room temperature on a rocker 
platform protected from light. After incubation the labeled samples were centrifuged at 
5600 rpm for 5 min, the supernatant was discarded, and the cells were resuspended in 1 
ml of 1X PBS.  Following this, the optical density (O.D) was measured at 600 nm from 
ten-fold diluted cultures of S. gordonii to determine cell count. 
For all experiments, the optical density of S. gordonii cells was adjusted to 0.8 
for uniformity of the S. gordonii cell amounts in each well. After adjusting the optical 
density, 1 ml of S. gordonii cells was added to a 12 well culture plate containing a 
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sterilized micro-coverslip in each well. The 12 well cell culture plate was wrapped in 
aluminum foil to protect the labeled cells from light and placed on a rocker platform in 
the anaerobic chamber for 24 hr.  
P. gingivalis cultures used for biofilm formation were optimized using a similar 
approach. Briefly, 12 ml of P. gingivalis cells were centrifuged for 5 min at 5600 rpm. 
The supernatant was discarded and the cell pellet was resuspended in 1 ml of pre-
reduced 1X PBS. P. gingivalis cells were labeled with 20 µl of carboxyfluorescein–
succinylester (4 mg/ml, Molecular Probes). Cells were incubated with the fluorescent 
dye for 30 min and protected from light. Following incubation, cells were centrifuged at 
10000 rpm for 1 min and the supernatant was discarded to remove the unbound 
fluorescent dye. The pelleted cells were resuspended in 1ml of pre-reduced 1X PBS.  
Previous experiments showed that the optimal inoculum for P. gingivalis was a 
cell suspension that was adjusted to an optical density of 0.4. For biofilm inhibition 
assays using BAR-NPs, the initial optical density (600 nm) was adjusted to 0.8 and the 
cell suspension was subsequently diluted with an equal volume of the BAR-NP 
suspension to generate a final O.D. 600 nm of 0.4. For biofilm inhibition experiments, 
BAR-NPs or soluble BAR peptide was pre-incubated with labeled P. gingivalis cells at 
peptide concentrations ranging from 0 to 10 µg/ml at 25°C for 30 min before 
transferring to the appropriate wells. The 12 well cell culture plate was covered with 
aluminum foil and incubated for 18-24 hr in an anaerobic chamber.  
Following incubation, the supernatant was removed from the wells of the 12 well 
cell culture plate and the cells were washed with pre-reduced 1X PBS to remove non-
adherent bacterial cells. The cells were subsequently fixed with 4% (w/v) using 
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paraformaldehyde, excess paraformaldehyde was removed, and the cells were washed 
with pre-reduced 1X PBS. The coverslip was then mounted on to a glass slide using 
















Figure	   5:	   Dual Species Biofilm Assay: (1) S. gordonii cells were labeled with 
Hexidium iodide, added to micro-coverslips in a 12 well cell culture plate, and 
incubated. (2) After removal of the supernatant, P. gingivalis cells labeled with 
carboxyfluorescein 5, 6- succinyl ester were incubated with the BAR-modified NPs, 
added to the micro-coverslips, and incubated anaerobically. After 24 hr incubation, the 
coverslips were fixed and mounted onto slides and visualized using Olympus Fluoview 
FV500 Laser Scanning Microscopy.	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Confocal Microscope 
P. gingivalis-S. gordonii biofilms were visualized using an Olympus Fluoview 500 
confocal laser scanning microscope (Olympus, Pittsburgh, PA). The slides were viewed 
using an argon laser for visualization of FITC-labeled P. gingivalis and the HeNe-G 
laser to visualize hexidium iodide- labeled streptococci.  P. gingivalis binding was 
determined from 30 to 60 randomly chosen frames using FluoView Software.  Z-stack 
images of the biofilms were obtained using a z-step size of 0.7 µm and images were 
analyzed with the Volocity image analysis software.  
 
Image Analysis 
After obtaining the images from confocal microscopy, the resulting z-stack 
images were processed and reconstructed into 3D images using the Volocity software. 
Images were imported into Volocity as multiple Tiff-files. Uniform filters were used to 
remove noise from the images and were further analyzed to quantify the extent of P. 
gingivalis binding. The image brightness and contrast was adjusted equally for all 
frames, and a snapshot of the image was captured. Next, the ratio of green to red 
fluorescence was determined. Each peptide concentration was analyzed in triplicate and 
3 independent frames were measured for each well. The mean and variation (SD) 
between samples was determined using ANOVA. The variation was considered 
statistically significant when P<0.05. 
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          CHAPTER 4 
 
                                                    RESULTS 
	  
	  
Nanoparticle Synthesis and Characterization 
 
Previous studies have demonstrated the utility of coupling peptides to NP surfaces 
via avidin-biotin ligands (Av-ligand) 41.  In this study both the unmodified and BAR-NPs 
led to NPs of comparable size (Figure 6A).  Analysis of SEM images shows the average 
NP diameters of 98±28 and 134±28 nm for unmodified and BAR-NPs, respectively. As 
expected, the presence of BAR on the NP surface did not significantly change the size of 
the NPs (P>0.05). Furthermore, no change was seen in the characteristic texture and 
morphology after surface conjugation, relative to unmodified NPs. NP surface charge 
was measured by zeta potential, and DLS was used to measure the hydrodynamic 
diameter (Figure 6B). Average hydrodynamic diameters determined via DLS were 
298±13 nm and 329±10 nm for the unmodified and BAR-NPs, respectively. As expected 
the diameters measured for hydrated NPs using DLS were slightly higher than the 
diameters of unhydrated NPs analyzed with SEM.   
  NP surface charge and hydrodynamic diameter were used to predict the long-term 
stability and surface-modification of the NPs. Zeta potential values were measured for 
NPs with avidin and BAR surface modification (Figure 6C). Unmodified NPs exhibited a 
negative charge of -25 mV. Addition of avidin to the NPs produced more positive zeta 
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potentials, which correlated with increased avidin density on the NP surface. When BAR 
was added to avidin-NPs, the zeta potential was slightly, but not significantly more 
positively charged, correlating with increased ligand conjugation. This is consistent with 
the net positive charge of BAR.  Furthermore, there was a significant difference in zeta 
potential between the unmodified and avidin-NP groups and unmodified and BAR-NP 
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Surfae Modification Efficacy and Functionality of PLGA-NPs	  	  
To determine and optimize the amount of BAR peptide incorporated on the 
surface of the PLGA NPs, we utilized two different detection methods, an indirect 
method (biotin-PEG-FITC binding reaction) and a direct method (fluorescently-labeled 
BAR binding). The results from both the direct and indirect assays allowed us to optimize 
the synthesis and conjugation conditions to obtain maximal binding of BAR to the NP 
surface. 
Quantification of the Total Biotin Binding Sites.  	  
The incorporation of avidin on avidin-NPs was determined using the microBCA 
assay. The estimate of the number of available biotin binding sites was important for 





Figure 6: (A) SEM images of unmodified and BAR-NPs and their corresponding 
distribution of NP diameter. (B) DLS values of NP  hydrodynamic diameters. (C) Zeta 
potential values of all NPs. The surface charge on unmodified and BAR-NPs was 
statistically significant (P<0.01) 
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present on the surface per milligram NPs which was similar to the amount of avidin 
added to the synthetic reaction.  This indicates that 100% of the input avidin (3.0 
nmol/mg) was incorporated on the NP surface. Next the amount of avidin was converted 
into molecules of avidin per NP. This conversion indicated that 3940 molecules of avidin 
were present per NP. Although avidin has 4 biotin binding sites, we assumed that each 
molecule would only have 2 accessible biotin binding sites and the remaining 2 sites 
would be inaccessible due to steric hindrance. Hence, we calculate that 3.1 nmol/mg 
(3940 molecules/NP) of avidin would bind 6.2 nmol/mg (7880 molecules/NP) of BAR.  
 
Indirect (Biotin-PEG-FITC Binding Experiment) 	  
In this experiment, we compared the fluorescence of avidin-NPs and BAR-NPs 
that were both treated with biotin-PEG-FITC to determine the number of available biotin 
binding sites before and after conjugation with biotinylated BAR. Biotin-PEG-FITC is 
comprised of PEG with a molecular weight of 3400 to closely match the molecular 
weight of BAR (3326 Da).  Biotin-PEG-FITC was conjugated with both avidin-NPs and 
BAR-NPs at a ratio of 3:1 biotin-PEG-FITC: biotin-binding sites (18.5 nmol/mg biotin-
PEG-FITC). Fluorescence of the resulting NPs was measured in triplicate and the mean 
fluorescence was quantified. The fluorescence values obtained were converted to an 
amount of PEG-FITC using a standard curve derived from increasing concentrations of 
biotin-PEG-FITC.  Subtracting the level of biotin-PEG-FITC incorporated into BAR-NPs 
from the amount incorporated into avidin-NPs using Equation 1 allowed us to indirectly 
determine the number of BAR peptides present on the surface of BAR-NPs. Table 2 
shows the number of biotin-PEG-FITC molecules per NP with the respective surface 
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modification.  As expected, we found the surface density of biotin-PEG-FITC on BAR-
NPs to be significantly less than biotin-PEG-FITC bound to avidin-NPs. Using a 3-fold 
(3:1) molar excess of biotin to avidin, 4.05 nmol/mg of biotin-PEG-FITC (5170 
molecules/NP) was bound to avidin-NPs occupying 65 percent of the total biotin binding 
sites on the avidin-NP surface (Table 2). In contrast, when avidin-NPs were first 
conjugated with biotin-BAR and reacted biotin-PEG-FITC, 0.12 nmol/mg of biotin-PEG-
FITC (149 molecules/NP) was incorporated on the surface of the BAR-NPs, occupying 
only 2% of the biotin binding sites, suggesting that 98% of the available biotin binding 






Direct (Fluorescently Labeled BAR Binding Experiment) 
To more directly determine the level of BAR incorporated after conjugation of avidin-
NPs, we titrated avidin-NPs with 3-, 6-, 9- and 18- fold molar excess (18.5 – 111.2 
nmol/mg) of fluorescently-labeled BAR (BAR-Flc). NPs were reacted with 
concentrations higher than 18.5 nmol/mg as the 3-fold excess used in indirect binding 
experiment indicated that higher concentration was needed for saturating the available 
avidin binding sites. NPs were incubated with BAR-Flc for 1 hr, washed, lyophilized, and 
Table 2:  Biotin-PEG-FITC surface density of avidin-NPs and BAR-NPs. The number of 
avidin molecules per NP was determined by the microBCA assay. It was assumed that 
each molecule of avidin subsequently bound two molecules of Biotin-PEG-FITC. 
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fluorescence was quantified as previously described. The incorporation of BAR-Flc on 
avidin-NPs was directly related to concentration of BAR-Flc added. As shown in Figure 
8, we observed that saturation of BAR-Flc binding occurred with an input concentration 
of 37.1 nmol/mg (6- fold molar excess of calculated biotin binding sites) indicating that 
at this input concentration, all of the available biotin sites were bound with BAR-Flc. 
Mean fluorescence values did not significantly increase when NPs were conjugated with 
higher concentrations of BAR-Flc (Figure 8). Using a 3-fold (3:1) molar excess of BAR 
to avidin, 3.85 nmol/mg of BAR-Flc (4910 molecules/NP) was bound to avidin-NPs 
occupying 62.3% of the total biotin binding sites on the avidin-NP surface (Table 3). At 
the saturation concentration of 37.1 nmol/mg (6 fold molar excess of calculated biotin 
binding sites), 7.42 nmol/mg of BAR-Flc (9460 molecules/NP) was incorporated on the 
surface of the avidin-NPs, occupying 100% of the biotin binding sites. Furthermore, 
BAR-flc binding did not significantly increase when NPs were conjugated with higher 










Table	   3: Biotin-Flc surface density of avidin-NPs and BAR-NPs. The number of avidin 
molecules per NP was determined by the microBCA assay. The concentration of BAR-Flc 
obtained from the direct characterization was converted into the number of bound BAR-
Flc per NP.  
*Assuming that each molecule of avidin have two binding sites. 	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Figure 7: Saturation curve of BAR-Flc. Avidin-NPs were reacted with a 3-, 6-, 9-, 18- 
fold molar excess of BAR-Flc (18.5 – 111.2 nmol/mg NP) and the NP bound 
Fluorescence was determined and plotted. 	  	  
To determine if BAR-NPs were functional, we evaluated BAR-NP binding to P. 
gingivalis. BAR-NPs encapsulating the fluorophore C6 were incubated with P. gingivalis 
cells and cell-bound fluorescence was measured. In these experiments, the BAR-NP 
concentration was determined using total NP mass. As shown in Fig. 9, BAR-NPs bound 
to P. gingivalis cells in a dose-dependent manner. These results demonstrated proof-of-
concept that uniformly sized BAR-NPs interact with P. gingivalis in a dose-dependent 
manner  
  






Figure 8: Dose Dependent binding of BAR-NPs with encapsulated C6 to P. gingivalis. 
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BAR Inhibits Formation of P. gingivalis Biofilms 
 
 
To determine if BAR-NPs competitively inhibit P. gingivalis adherence to 
streptococcal cells and prevent biofilm development, P. gingivalis biofilms were formed 
on immobilized streptococci in the presence of increasing concentrations of BAR-NPs 
for 24 hr. Previous studies showed that soluble BAR had an IC50 (50% inhibitory 
concentration) of 1.3 µM. Therefore, in these experiments, the amount of BAR on the 
surface of BAR-NPs was calculated using the direct binding results and sufficient 
amounts of NPs to deliver BAR peptide concentrations ranging from 0.3 to 1.7 µM were 
tested and compared with similar concentrations of free soluble BAR.   
       P. gingivalis adherence to the immobilized streptococci was visualized using 
confocal scanning microscopy and the ratio of green (P. gingivalis) and red (S. gordonii) 
fluorescence was quantified using Volocity image analysis software.  For control 
reactions, P. gingivalis was incubated with streptococci in the presence of buffer alone. 
The representative	   images	  of	  biofilms	   formed	   in	   the	  presence	  of	  BAR-­‐NPs	  or	  soluble	  BAR	  are	  shown	  in	  Figure	  10.	  As summarized in Table 3, BAR-NPs exhibited dose dependent 
inhibition of biofilm formation with the ratio of green to red fluorescence being 
significantly reduced (P<0.01) at all concentrations.  The striking result was that BAR- 
NPs more potently inhibit P. gingivalis adherence than soluble BAR.   
 
 
	  34	  	  
	  	  	  	  	  	  	  	  	  
Figure 9: Comparison of BAR and BAR-NP inhibition of P. gingivalis and S. gordonii  	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These results show that NPs surface-modified with BAR peptide more potently 
inhibit P. gingivalis adherence to S. gordonii (IC50 ~ 0.29 µM) than soluble (IC50 = 1.3 
µM), indicating that BAR-NPs are approximately 4.5 times more potent than soluble 
BAR.  This suggests that BAR-NPs may promote multivalent interaction with P. 
gingivalis and that surface modified NPs may represent a viable mechanism to deliver 
higher localized concentrations of BAR peptide to the biofilm. Together, the results 
	  
	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Figure 10: P. gingivalis inhibition plot of BAR-Flc and soluble BAR obtained from the dual  
                              species biofilm assay. P. gingivalis was reacted with increasing concentration (0.3- 1.7µM)  
                              of BAR-NPs and the percentage inhibition of  P. gingivalis microcolonies were determined  
                              and plotted. 
	  
Table 3: Dose response of free BAR peptide and BAR-NPs in P. gingivalis-S. gordonii dual 
species biofilms. 	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provide proof-of-principle that targeted antimicrobial NPs can be utilized to control the 
complex biofilm associated with periodontal disease.  
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                                                   DISCUSSION 
 
The human oral cavity presents a hostile environment to microorganisms as a 
result of the constant flow of saliva that contains numerous antimicrobial agents11. The 
early colonizers protect themselves from these conditions by forming multispecies 
biofilms with other resident organisms11. The periodontal pathogen P. gingivalis faces 
different challenges in colonizing the oral cavity since it is an obligate anaerobe that is 
acid-sensitive and requires hemin as an essential growth factor11. Therefore, its primary 
niche is the subgingival pocket but before establishing itself in that niche, it must first 
survive in relatively aerobic supragingival environment11,23,24. To accomplish this, P. 
gingivalis interacts with the primary colonizer S. gordonii that provides a physiologically 
compatible local environment for P. gingivalis11.  Since this interaction is one of the 
initial events that leads to P. gingivalis colonization of the oral cavity, it represents an 
ideal target for therapeutic intervention to limit P. gingivalis colonization and potentially 
reduce adult periodontitis11,22,23.  Previous studies have been successful identifying the 
mechanisms of this interaction and adherence between P. gingivalis and S. 
gordonii11,23,24. It was found that the Mfa1 of P. gingivalis interacted with SspB of S. 
gordonii. Furthermore, P. gingivalis showed binding specificity with streptococcus 
gordonii and it did not adhere to Streptococcus mutans, which expressed SpaP, a highly 
conserved homolog of SspB. These studies led to the development of BAR peptide, 
	  38	  	  
which is derived from the antigen I/II protein of S. gordonii and functions as a potent 
inhibitor of P. gingivalis adherence to S. gordonii. Corresponding a peptide derived from 
SpaP of S. mutants showed that it did not interact with Mfa1 of P. gingivalis. In addition, 
BAR significantly reduced P. gingivalis virulence in mice that harbor S. gordonii when 
administered simultaneously with P. gingivalis infection11,23. However, although BAR 
potently inhibits the formation of two species biofilms, it is less effective in disrupting 
established biofilms or more complex biofilms, requiring higher concentrations and 
prolonged exposure to be effective. In this study, it was hypothesized that targeted 
nanoparticles comprised of an FDA-approved polymer, PLGA, and surface modified with 
BAR may enhance the potency of the peptide via two mechanisms: 1) by delivering BAR 
at higher localized concentration to P. gingivalis and 2) by promoting a multivalent 
binding interface to increase the avidity of BAR with P. gingivalis.  
In this study a reproducible and rapid preparation method was developed to 
synthesize unmodified and BAR-NPs. Previous studies have demonstrated that avidin-
biotin-ligand conjugation provides one of the strongest non-covalent bonds, while 
offering a flexible, tunable, and efficient method to conjugate and alter ligand density on 
the NP surface41. The	  synthetic	  process that was developed resulted in the production of 
spherical unmodified and BAR-modified NPs with a narrow particle size distribution 
(size about 100-134 nm). Additionally, we observed a negative surface charge for 
unmodified NPs but a slightly positive charge for BAR-NPs.  This disparity of charge can 
be explained by the carboxyl groups of PLGA for unmodified NPs and the presence of 
cationic molecules, i.e., avidin and BAR on the surface of modified NPs41. Furthermore, 
the zeta-potential values for both unmodified (-25 mV) and BAR-NPs (-10 mV) are in 
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agreement with other unmodified and avidin-NP studies, where, unmodified PLGA NPs 
typically have a negative surface charge and avidin-modified NPs display a more positive 
surface charge. The statistically significant (P<0.01) surface charge that we observed 
between unmodified-NPs and BAR-NPs was attributed to successful conjugation with the 
positively-charged BAR peptide. For biological experiments, this positive zeta potential 
may also be beneficial as the positive NP surface charge might facilitate the interaction of 
NPs with P. gingivalis by promoting electrostatic attractions with the negative moieties 
on the bacterial cell membrane.  
To design a NP formulation with maximal levels of BAR peptide, it was 
important to first quantify the number of avidin molecules present on the NP surface and 
available for subsequent BAR conjugation. To estimate the number of molecules of 
avidin per NP, we used the microBCA assay to confirm 100% incorporation of the input 
avidin to the NP surface. Although under these conditions, we were able to achieve 
virtually 100% incorporation of avidin on the NP surface, we believe that these NPs have 
greater potential to incorporate more avidin on its surface. One way to confirm this is to 
determine the level of avidin saturation for the NPs. After quantifying the amount of the 
avidin, we next calculated the number of biotin binding sites that may be available for 
ligand binding. Each avidin has four biotin binding sites; however, the binding sites are in 
close proximity to each other and the NP surface, which may lead to steric 
hindrance41.  Hence, we assumed that only 2 biotin-binding sites per avidin molecule 
would be available for interaction with biotinylated-BAR. 
To experimentally determine the ligand concentration required to saturate the 
available biotin binding sites, we reacted avidin-NPs and BAR-NPs with a 3-fold molar 
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excess of biotin-PEG-FITC (18.5 nmol/mg). Our results show that when biotin-PEG-
FITC was reacted with avidin-NPs, biotin-PEG-FITC occupied only 65% (4.05 nmol/mg) 
of the available binding sites. This result suggests, that 18.5 nmol biotin-PEG-FITC per 
mg of avidin NP is not sufficient to saturate the available binding sites.  When avidin-
NPs were first reacted with 18.5 nmol/mg biotinylated-BAR and subsequently with 
biotin-PEG-FITC, only 2% of the biotin binding sites bound to biotin-PEG-FITC, 
suggesting that 98% of the available biotin binding sites were occupied by biotinylated 
BAR.   
Since it was possible in the experiments above that 18.5 nmol biotin-PEG-FITC 
per mg avidin-NP was insufficient to saturate the biotin binding sites, a direct approach 
was used to quantify the amount of BAR bound to the NP surface using a fluorescein 
labeled peptide (BAR-Flc). For these experiments, BAR-Flc was reacted with avidin-NPs 
at a concentration range of 18.5, 37.1, 55.6 and 111.2 nmol/mg avidin-NPs (representing 
3-, 6-, 9-, and 18-fold molar excess of BAR-Flc relative to the calculated biotin binding 
sites available) and NP bound fluorescence was determined. The results from this 
experiment were consistent with the indirect assay in that a 3-fold molar excess (18.5 
nmol/mg) of BAR-Flc occupied approximately 62% of the available biotin sites. We 
previously assumed that each avidin molecule would only have 2 accessible biotin 
binding sites. From the microBCA, this assumption would indicate that 3.1 nmol/mg of 
avidin incorporated on the NP surface bind 6.2 nmol/mg of BAR. However, at an input 
concentration of 37.1 nmol/mg of BAR-Flc (6- fold molar excess), we discovered 7.4 
nmol/mg of BAR-Flc was incorporated on the surface of avidin-NPs. This indicated that 
Avidin-NPs were saturated with BAR-Flc at an input concentration of 37.1 nmol/mg 
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avidin-NPs. Given this result, further conjugation reactions with BAR were carried out 
using 55.6 nmol of BAR-Flc per mg avidin-NPs and no significant additional BAR-Flc 
binding was observed. Together these results indicate that the assumption of two biotin 
binding sites was conservative and that few of the NPs had 3 available binding sites.  
 To assess the function of BAR-NPs, we compared the ability molar equivalent 
amounts of BAR peptide carried by BAR-NPs and soluble BAR to inhibit P. gingivalis 
adherence to S. gordonii.  As shown in Figure 10, both soluble BAR and BAR-NPs 
inhibited P. gingivalis adherence in a dose dependent manner.  However, BAR-NPs more 
potently inhibited P. gingivalis adherence relative to soluble BAR.  The IC50 of BAR-
NPs was significantly lower (<0.3 µM) than soluble BAR (IC50 1.3 µM).    
It is reported in many other studies that NPs that bind a large number of ligands 
show increased drug efficacy by promoting a multivalent binding interface41. In our 
experiments, we believe that BAR-NPs followed a similar mechanism of increased 
efficacy.  In the future, we expect to develop mechanisms to identify the role that ligand 
number and ligand type plays in multivalent interaction between NP-ligands and a 
targeted receptor. Though the current approach does not provide comprehensive 
information about the binding kinetics of synthetic multivalent NPs, our analyses has an 
impact on the real-world biopharmaceutical development by providing a theoretical 
framework for designing future NPs that are better suited for targeting other 
microorganisms in oral biofilms. We also recognize that the etiology of periodontal 
disease is complex, and although recent evidence suggests that P. gingivalis may play an 
essential role in altering host-microbe homeostasis, other pathogens or pathogen 
interactions may have a significant impact on disease progression. Therefore, while these 
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delivery approaches will be initially applied to target BAR peptide to P. gingivalis 
niches, NPs might have broader applicability for targeting several other oral bacteria. 
This could be achieved for example, by co-modifying the surface of NPs with several 
other antimicrobial agents targeting other bacteria in the oral cavity. Furthermore, NPs 
could be co-modified with cell-surface adhesive proteins to increase retention times of 
these NPs in the oral cavity.  
Our results suggest that BAR-NPs show a striking advantage at low 
concentrations and result in significantly higher inhibition of P. gingivalis adherence to S. 
gordonii than soluble BAR. We believe that the greater efficiency of BAR-NPs at lower 
concentrations can be helpful for the future development of therapeutic formulations such 
as a mouth rinse or chewing gum. In the oral cavity, the constant flow of saliva, the 
intake of food and water and other factors may reduce the levels of therapeutic NPs (i.e., 
wash out).  Thus, the effectiveness of BAR may be reduced with time and approaches to 
increase the potency of the peptide. Due to the efficacy of BAR-NPs at both high and low 
concentrations, relative to soluble BAR, the beneficial activity of BAR may be well-
suited to this open flow environment.  Overall, our experiments show that we have a 
reliable and defined method of modifying NPs with inhibitory peptides. Our results 
suggest that nanotechnology can be efficiently used to combat oral pathogens and reduce 
oral diseases. It has been recently established that NPs are a proven platform for 
numerous infectious disease2. Hence the use of NP based drug delivery system to target 
specific organisms and niches in the oral microbiome represents a novel approach to 
combat periodontal disease. 
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Future studies will focus on developing alternative approaches of NP synthesis 
which incorporate more avidin per NP thereby further increasing the payload of BAR. 
Furthermore, assessing the efficacy of BAR-NPs by incorporating changes in the density 
of BAR surface modification. Furthermore, investigations will focus on the ability of 
BAR-NPs to reduce P. gingivalis virulence using the modified Baker mouse model of 
periodontitis. Together, the results from these experiments may provide proof-of-
principle of the efficacy with which surface-modified targeted antimicrobial NPs can be 
utilized to control the complex biofilm associated with periodontal disease. Furthermore, 
additional studies will focus on synthesizing and characterizing targeted PLGA NPs that 
encapsulate BAR to provide an alternative platform that offers prolonged-release of the 
peptide. Following this, experiments will be done to examine the toxicity of modified and 
sustained release NPs against human oral gingival and innate immune cells, and methods 
to formulate NP preparations. The long-term goal is to develop a formulation that can be 
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